Drug Channels

FEBRUARY 23, 2021

In this issue: Payers confess: Patients lose from copay accumulators Humana joins the Express Scripts GPO Hospitals vs. PBMs over specialty pharmacy white bagging Let’s all follow the Buy-and-Bill Dollar! Plus, entrepreneurial pharmacy owner Dave Marley demonstrates the power of innovation. Sometimes, the little guy wins big.

Pharmacy 52

Pharmacy Specialty Pharmacies Hospitals Independent Pharmacies 52

Common Sense for Drug Policy Blog

JANUARY 5, 2024

Part of this 'performance' has to do with adapting to the different temporal demands of the labor market—in other words, the management of sleep and wakefulness. In the current 'gig economy' — dominated by those jobs in which people are paid by the task, rather than receiving a fixed salary — work never stops. As Crary ( 2013 , p.

Pharmacy 52

Pharmacy Regulations Production Marketing 52

The Pharma Data

NOVEMBER 11, 2020

From 1965 until 1978, Dr. McChesney served as a faculty member at the University of Kansas School of Pharmacy, who presented him with an Outstanding Teaching Award for the 1967 to 1968 academic year. departing in 2003 to become the chief scientific officer for Tapestry Pharmaceuticals and ChromaDex Inc.

Organic Chemistry 52

Organic Chemistry Science Pharmacy Pharmaceuticals 52

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. CHPA predicted that the removal of oral phenylephrine from the market would lead to significant burden to both consumers and the healthcare system.

Science 40

Science FDA Clinical Trials Clinical Pharmacology 40

Drug & Device Law

MAY 26, 2023

The word “generic” in that sentence was not limiting, as the logic applied more broadly: “Nor could such a state law duty exist, as it would directly conflict with the federal statutory scheme in which Congress vested sole authority with the FDA to determine whether a drug may be marketed in interstate commerce.” Id. Walsh , 538 U.S.

Regulations 59

Regulations Production FDA FDA Approval 59

Drug & Device Law

FEBRUARY 20, 2023

In product liability litigation generally, plaintiffs have been allowed to invent all kinds of “alternative” designs as long as some “expert” opines that the design (even if never before marketed) is “feasible.” 2003), aff’d , 810 N.Y.S.2d For physicians to prescribe such a safer drug, it must reach the market. 2d 506 (N.Y.

FDA 59

FDA FDA Approval Testimonials Vaccine 59

Drug & Device Law

JANUARY 4, 2024

2003); Birdsong v. purchase, marketing, promotion, . . Alabama State Board of Pharmacy , 61 F.4th Okuley’s Pharmacy & Home Medical , N.E.3d development, clinical testing or investigation, distribution, purchase, marketing, promotion, sale, purchase, or use” of an immune covered countermeasure. Ogle , 108 S.W.3d

Vaccine 59

Vaccine FDA FDA Approval Production 59